GRAPHITE BIO INC (GRPH) Stock News
NASDAQ:GRPH - Nasdaq - US38870X1046 - Common Stock - Currency: USD
GRPH Latest News, Press Relases and Analysis
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are a great way to start the week as we check out all of the biggest trades happening on Monday morning!
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
GRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPH
Gene editing stocks mixed despite world’s first CRISPR drug
Gene editing stocks were mixed even after CRISPR Therapeutics (CRSP) and Vertex Pharma (VRTX), in a world's first, won U.K. nod for a CRISPR-based drug. Read more here.
Shareholder Alert: Ademi LLP investigates whether Graphite Bio, Inc. has obtained a Fair Price in its transaction with LENZ Therapeutics
/PRNewswire/ -- Ademi LLP is investigating Graphite Bio (NASDAQ: GRPH) for possible breaches of fiduciary duty and other violations of law in its transaction...
GRPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Graphite Bio, Inc. Is Fair to Shareholders
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
Graphite Bio CFO resigns to pursue other opportunities (NASDAQ:GRPH)
Graphite Bio (GRPH) CFO Alethia Young to step down to pursue other opportunities.Ms
Graphite Bio Announces Departure of Chief Financial Officer
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
GRPH stock gains even as downgrades pile up (NASDAQ:GRPH)
Graphite Bio (GRPH) gained Thursday, even as Wall Street analysts downgraded it following its decision to halt research into a sickle cell disease candidate. Read the full story here.
Mentions: BAC
Graphite Bio stock up 19% despite 50% workforce reduction (NASDAQ:GRPH)
Graphite Bio (GRPH) would reduce the company’s workforce by ~50% as a part of corporate restructuring and will reduce cash burn.The company has decided to discontinue further development...
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
Graphite Bio in the red after downgrade by BofA Securities (NASDAQ:GRPH)
Graphite Bio (GRPH) was down around -9% on Wednesday after BofA Securities downgraded the stock to Neutral from Buy, with a price target of $3 (down from $7).BofA Securities analysts...